TCW Group Inc. Increases Stake in Fulgent Genetics, Inc. (NASDAQ:FLGT)

TCW Group Inc. grew its stake in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) by 3.0% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 120,100 shares of the company’s stock after purchasing an additional 3,500 shares during the quarter. TCW Group Inc. owned approximately 0.40% of Fulgent Genetics worth $2,356,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Louisiana State Employees Retirement System purchased a new stake in shares of Fulgent Genetics during the fourth quarter worth about $292,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Fulgent Genetics by 34.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,569 shares of the company’s stock worth $190,000 after buying an additional 1,667 shares during the last quarter. Illinois Municipal Retirement Fund increased its stake in shares of Fulgent Genetics by 5.6% during the fourth quarter. Illinois Municipal Retirement Fund now owns 12,534 shares of the company’s stock valued at $362,000 after buying an additional 668 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Fulgent Genetics by 14.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 267,313 shares of the company’s stock valued at $7,728,000 after buying an additional 33,141 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Fulgent Genetics by 11.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,447,153 shares of the company’s stock valued at $41,839,000 after acquiring an additional 147,505 shares in the last quarter. Institutional investors own 48.06% of the company’s stock.

Fulgent Genetics Stock Down 0.1 %

Shares of FLGT stock opened at $23.48 on Monday. The stock has a fifty day moving average of $21.64 and a 200 day moving average of $22.06. The firm has a market capitalization of $702.62 million, a price-to-earnings ratio of -4.22 and a beta of 1.37. Fulgent Genetics, Inc. has a 52 week low of $18.91 and a 52 week high of $34.83.

Fulgent Genetics (NASDAQ:FLGT) last announced its earnings results on Friday, August 2nd. The company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.45. Fulgent Genetics had a negative net margin of 57.72% and a negative return on equity of 2.92%. The firm had revenue of $71.03 million for the quarter, compared to analyst estimates of $69.07 million. During the same quarter in the previous year, the firm posted ($0.33) EPS. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. Equities research analysts anticipate that Fulgent Genetics, Inc. will post -2.12 earnings per share for the current year.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.